APA (7th ed.) Citation

SW, R., TLB, E., L, S., MB, S., EL, A., HK, N., . . . TA, M. (2023). Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies. Therapeutic innovation & regulatory science, 57(2), 386. https://doi.org/10.1007/s43441-022-00477-y

Chicago Style (17th ed.) Citation

SW, Roberts, et al. "Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies." Therapeutic Innovation & Regulatory Science 57, no. 2 (2023): 386. https://doi.org/10.1007/s43441-022-00477-y.

MLA (9th ed.) Citation

SW, Roberts, et al. "Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies." Therapeutic Innovation & Regulatory Science, vol. 57, no. 2, 2023, p. 386, https://doi.org/10.1007/s43441-022-00477-y.